|
126 Companies |
|
141 Products |
|
141 Products |
|
89 Mechanisms of Action |
|
9 Trials |
|
1237 News |
|
| «12345678910111213...2425» |
- Trial termination: Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer (clinicaltrials.gov) - Oct 3, 2015
P2, N=7, Terminated, Sponsor: Alliance for Clinical Trials in Oncology
Completed --> Terminated; Slow accrual
- Trial completion: Zinc Supplements in Lowering Cadmium Levels in Smokers (clinicaltrials.gov) - Oct 3, 2015
P2, N=61, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
Completed --> Terminated; Slow accrual Active, not recruiting --> Completed
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., docetaxel / Generic mfg.
Trial primary completion date, Metastases: Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor (clinicaltrials.gov) - Oct 1, 2015
P1/2, N=58, Active, not recruiting, Sponsor: Northwestern University
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Dec 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Sep 30, 2015
P1, N=43, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: POINTS: Post-Operative Impact of Nasogastric Tubes on Rates of Emesis in Infants Diagnosed With Pyloric Stenosis (clinicaltrials.gov) - Sep 28, 2015
P0, N=50, Completed, Sponsor: Hamilton Health Sciences Corporation
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Sep 2012 --> Jan 2015
- Enrollment change, Trial withdrawal, Trial primary completion date, Surgery: Educational Brochure in Preparing Patients With Gastric Cancer and Their Caregivers for Recovery After Surgery (clinicaltrials.gov) - Sep 25, 2015
P=N/A, N=0, Withdrawn, Sponsor: City of Hope Medical Center
Recruiting --> Completed | Trial primary completion date: Sep 2012 --> Jan 2015 N=20 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: May 2016 --> Sep 2015
- || AMG 337 / ImmunityBio, Amgen
Trial primary completion date: Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors (clinicaltrials.gov) - Sep 24, 2015
P2, N=60, Active, not recruiting, Sponsor: Amgen
N=20 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: May 2016 --> Sep 2015 Trial primary completion date: Sep 2015 --> Apr 2016
- |||| TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon
Trial primary completion date, Combination therapy, Monotherapy, Metastases: Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer (clinicaltrials.gov) - Sep 24, 2015
P3, N=400, Recruiting, Sponsor: Kuhnil Pharmaceutical Co., Ltd.
Trial primary completion date: Sep 2015 --> Apr 2016 Trial primary completion date: Dec 2014 --> Jan 2018
- Gilotrif (afatinib) / Boehringer Ingelheim
Trial primary completion date, Combination therapy: Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer. (clinicaltrials.gov) - Sep 24, 2015
P1, N=13, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Dec 2014 --> Jan 2018 Trial primary completion date: Aug 2015 --> Nov 2015
- SM04755 / Biosplice Therap
Trial suspension, Metastases: Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer (clinicaltrials.gov) - Sep 22, 2015
P1, N=25, Suspended, Sponsor: Samumed LLC
Trial primary completion date: Aug 2015 --> Nov 2015 Recruiting --> Suspended
- || Enrollment closed, Enrollment change, Trial primary completion date: Clinical Management With SPM System and Validation of the SPM 5 Hour Cutoff in Patients With Symptoms of Gastroparesis (clinicaltrials.gov) - Sep 22, 2015
P=N/A, N=172, Active, not recruiting, Sponsor: Medtronic - MITG
Recruiting --> Suspended Recruiting --> Active, not recruiting | N=250 --> 172 | Trial primary completion date: Jan 2016 --> May 2016
- Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment closed, Trial primary completion date, Metastases: MOMENTUM1: Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers (clinicaltrials.gov) - Sep 17, 2015
P1, N=42, Active, not recruiting, Sponsor: Jules Bordet Institute
Recruiting --> Active, not recruiting | N=250 --> 172 | Trial primary completion date: Jan 2016 --> May 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Oct 2015
- | Signifor LAR (pasireotide long acting release) / Recordati
Trial completion: Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome (clinicaltrials.gov) - Sep 14, 2015
P2, N=43, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Oct 2015 Active, not recruiting --> Completed
- Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Trial completion, Trial primary completion date: Is Rebamipide Effective on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection? (clinicaltrials.gov) - Sep 4, 2015
P=N/A, N=290, Completed, Sponsor: Kangdong Sacred Heart Hospital
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Aug 2010 --> Dec 2010
- clarithromycin / Generic mfg., esomeprazole / Generic mfg.
Trial completion, Head-to-Head: Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy (clinicaltrials.gov) - Sep 3, 2015
P4, N=612, Completed, Sponsor: Xijing Hospital of Digestive Diseases
Recruiting --> Completed | Trial primary completion date: Aug 2010 --> Dec 2010 Recruiting --> Completed
- Enrollment change, Trial termination: The Size of the Gastric Remnant as Determinant for Delayed Gastric Emptying After Whipple Resection. (clinicaltrials.gov) - Sep 2, 2015
P2, N=7, Terminated, Sponsor: Karolinska University Hospital
Recruiting --> Completed N=120 --> 7 | Enrolling by invitation --> Terminated; Terminated due to insufficient inclusion rate.
- | Trial completion: Randomized Control Trial on Seprafilm and Guardix in Preventing Ileus (clinicaltrials.gov) - Sep 1, 2015
P3, N=200, Completed, Sponsor: Gachon University Gil Medical Center
N=120 --> 7 | Enrolling by invitation --> Terminated; Terminated due to insufficient inclusion rate. Recruiting --> Completed
- Trial completion, Biopsy: Rapid Urease Test for Diagnosis of H. Pylori Infection in Patients With Peptic Ulcer Bleeding (clinicaltrials.gov) - Aug 31, 2015
P=N/A, N=116, Completed, Sponsor: Far Eastern Memorial Hospital
Recruiting --> Completed Recruiting --> Completed
- bupropion / Generic mfg.
Trial completion: Bupropion in Helping Adults Stop Smoking (clinicaltrials.gov) - Aug 28, 2015
P2, N=97, Completed, Sponsor: Roswell Park Cancer Institute
Recruiting --> Completed Active, not recruiting --> Completed
- Herceptin (trastuzumab) / Roche
Trial completion, Combination therapy, Metastases: HerXO: Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive (clinicaltrials.gov) - Aug 27, 2015
P2, N=45, Completed, Sponsor: Fundaci
Active, not recruiting --> Completed Active, not recruiting --> Completed
- cantuzumab ravtansine (IMGN242) / AbbVie
Enrollment change, Metastases: huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas (clinicaltrials.gov) - Aug 26, 2015
P2, N=0, Withdrawn, Sponsor: ImmunoGen, Inc.
Active, not recruiting --> Completed N=45 --> 0
- Trial completion, Enrollment change: RCT: WLE vs. NBI in Upper Gastrointestinal Endoscopy (clinicaltrials.gov) - Aug 26, 2015
P=N/A, N=600, Completed, Sponsor: Changi General Hospital
N=45 --> 0 Active, not recruiting --> Completed | N=464 --> 600
- | Trial completion, Trial primary completion date, Biopsy: A Pilot Study on Usefulness of Probe-based Confocal Laser Endomicroscopy Targeted Gastric Biopsy (clinicaltrials.gov) - Aug 21, 2015
P=N/A, N=30, Completed, Sponsor: Yonsei University
Active, not recruiting --> Completed | N=464 --> 600 Recruiting --> Completed | Trial primary completion date: Aug 2015 --> Mar 2015
- Enrollment closed, Trial primary completion date: Capsule Endoscopy for Hemorrhage in the Emergency Room (clinicaltrials.gov) - Aug 19, 2015
P=N/A, N=50, Active, not recruiting, Sponsor: George Washington University
Recruiting --> Completed | Trial primary completion date: Aug 2015 --> Mar 2015 Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Oct 2013 --> Jun 2017
- |||| onartuzumab (RG3638) / Roche
Trial primary completion date, Combination therapy, Metastases: A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer (clinicaltrials.gov) - Aug 18, 2015
P3, N=564, Active, not recruiting, Sponsor: Hoffmann-La Roche
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Oct 2013 --> Jun 2017 Trial primary completion date: Jul 2015 --> Oct 2015
- rilotumumab (AMG 102) / Amgen
Trial termination, Trial primary completion date, Metastases: RILOMET-2: A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer (clinicaltrials.gov) - Aug 18, 2015
P3, N=34, Terminated, Sponsor: Amgen
Trial primary completion date: Jul 2015 --> Oct 2015 Active, not recruiting --> Terminated | Trial primary completion date: Oct 2017 --> Jun 2015; All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data Monitoring Committee safety review of study 20070622.
- oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Metastases: Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer (clinicaltrials.gov) - Aug 14, 2015
P1/2, N=44, Active, not recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Terminated | Trial primary completion date: Oct 2017 --> Jun 2015; All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data Monitoring Committee safety review of study 20070622. Trial primary completion date: Nov 2015 --> Apr 2016
- | rilotumumab (AMG 102) / Amgen
Trial termination, Trial primary completion date, Metastases: RILOMET-1: First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma (clinicaltrials.gov) - Aug 14, 2015
P3, N=610, Terminated, Sponsor: Amgen
Trial primary completion date: Nov 2015 --> Apr 2016 Active, not recruiting --> Terminated | Trial primary completion date: Mar 2016 --> Nov 2014; All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data Monitoring Committee safety review of study 20070622.
- | esomeprazole / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: IOE: Effect of IV and Oral Esomeprazole in Prevention of Recurrent Bleeding From Peptic Ulcers After Endoscopic Therapy (clinicaltrials.gov) - Aug 14, 2015
P3, N=263, Completed, Sponsor: Chinese University of Hong Kong
Active, not recruiting --> Terminated | Trial primary completion date: Mar 2016 --> Nov 2014; All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data Monitoring Committee safety review of study 20070622. Active, not recruiting --> Completed | N=406 --> 263 | Trial primary completion date: Apr 2015 --> Dec 2013
- aspirin / Generic mfg.
Trial primary completion date: ASP (PPI_H2RA) Study-H2RA Versus PPI for the Prevention of Recurrent UGIB in High-risk Users of Low-dose ASA (clinicaltrials.gov) - Aug 13, 2015
P3, N=332, Recruiting, Sponsor: Chinese University of Hong Kong
Active, not recruiting --> Completed | N=406 --> 263 | Trial primary completion date: Apr 2015 --> Dec 2013 Trial primary completion date: Apr 2015 --> Apr 2016
- Enrollment closed, Trial primary completion date: Early Selective TAE to Severely Bleeding Peptic Ulcers After Their Initial Endoscopic Hemostasis (clinicaltrials.gov) - Aug 12, 2015
P4, N=250, Active, not recruiting, Sponsor: Chinese University of Hong Kong
Trial primary completion date: Apr 2015 --> Apr 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Jul 2014
- Enrollment closed, Metastases: Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction (clinicaltrials.gov) - Aug 12, 2015
P2, N=96, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Jul 2014 Suspended --> Active, not recruiting
- Enrollment change, Trial primary completion date: Urgent vs. Early Endoscopy in High Risk Patients With Upper Gastrointestinal Bleeding (UGIB) (clinicaltrials.gov) - Aug 12, 2015
P4, N=516, Recruiting, Sponsor: Chinese University of Hong Kong
Suspended --> Active, not recruiting N=180 --> 516 | Trial primary completion date: Jul 2015 --> Jul 2016
- ||||| onartuzumab (RG3638) / Roche
Enrollment closed, Enrollment change, Combination therapy, Metastases: A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer (clinicaltrials.gov) - Aug 12, 2015
P3, N=564, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=180 --> 516 | Trial primary completion date: Jul 2015 --> Jul 2016 N=800 --> 564 | Recruiting --> Active, not recruiting
- ||||||| Liporaxel (paclitaxel oral) / Dae Hwa, HaiHe Biopharma
Trial completion, Trial primary completion date, Metastases: DREAM: Phase 3 Study to Compare Efficacy and Safety of DHP107 vs. Taxol (clinicaltrials.gov) - Aug 11, 2015
P3, N=238, Completed, Sponsor: Daehwa Pharmaceutical Co., Ltd.
N=800 --> 564 | Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Aug 2015
- Taptiqom (tafluprost/timolol) / Santen, AGC Biologics
Trial primary completion date, Head-to-Head: Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies (clinicaltrials.gov) - Jul 15, 2015
P1, N=64, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Aug 2015 Trial primary completion date: Apr 2015 --> Mar 2016
- || Enrollment closed, Trial primary completion date: Effect of Gastrectomy and Anastomosis on Diabetes and Hypertension in Early Gastric Cancer Patients (clinicaltrials.gov) - Jul 9, 2015
P=N/A, N=159, Active, not recruiting, Sponsor: National Cancer Center, Korea
Trial primary completion date: Apr 2015 --> Mar 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Feb 2016
- Trial completion, Enrollment change, Trial primary completion date: Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer (clinicaltrials.gov) - Jul 9, 2015
P2, N=7, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Feb 2016 Active, not recruiting --> Completed | N=75 --> 7 | Trial primary completion date: Aug 2011 --> Jan 2011
- || Herceptin (trastuzumab) / Roche
Trial primary completion date, Metastases: An Observational Study of Herceptin (Trastuzumab) in Patients With HER2-positive Advanced Gastric Cancer (clinicaltrials.gov) - Jul 2, 2015
P=N/A, N=443, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | N=75 --> 7 | Trial primary completion date: Aug 2011 --> Jan 2011 Trial primary completion date: Mar 2015 --> Apr 2016
- | Gilotrif (afatinib) / Boehringer Ingelheim
Enrollment closed, Combination therapy, Metastases: Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment (clinicaltrials.gov) - Jul 2, 2015
P2, N=36, Active, not recruiting, Sponsor: Columbia University
Trial primary completion date: Mar 2015 --> Apr 2016 Recruiting --> Active, not recruiting
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment closed, Metastases: SOPP: S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer (clinicaltrials.gov) - Jun 29, 2015
P3, N=338, Active, not recruiting, Sponsor: Min-Hee Ryu
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- cisplatin / Generic mfg., capecitabine / Generic mfg., docetaxel / Generic mfg.
Trial completion, Metastases: XPID: Safety Study of Combined Systemic and Intraperitoneal Chemotherapy to Treat Stomach Cancer (clinicaltrials.gov) - Jun 29, 2015
P1/2, N=37, Completed, Sponsor: Asan Medical Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial primary completion date: Motivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During Pregnancy (clinicaltrials.gov) - Jun 26, 2015
P=N/A, N=650, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Nov 2016 --> Nov 2017
- Folotyn (pralatrexate) / Aurobindo
Trial primary completion date, Combination therapy, Metastases: Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Jun 25, 2015
P2, N=35, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Nov 2016 --> Nov 2017 Trial primary completion date: Jun 2015 --> Jan 2015
- Trial primary completion date, Metastases: Efficacy of Laparoscopic Subtotal Gastrectomy With D2 Lymph Node Dissection for Locally Advanced Gastric Cancer (clinicaltrials.gov) - Jun 24, 2015
P3, N=1050, Active, not recruiting, Sponsor: Ajou University School of Medicine
Trial primary completion date: Jun 2015 --> Jan 2015 Trial primary completion date: Sep 2016 --> May 2018
- Herceptin (trastuzumab) / Roche
Trial primary completion date, IO biomarker: Safety Study of (clinicaltrials.gov) - Jun 23, 2015
P1, N=36, Active, not recruiting, Sponsor: Areva Med LLC
Trial primary completion date: Sep 2016 --> May 2018 Trial primary completion date: Dec 2014 --> Dec 2015
- || bupropion / Generic mfg.
Trial primary completion date: Bupropion in Helping Adults Stop Smoking (clinicaltrials.gov) - Jun 23, 2015
P2, N=97, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: May 2009 --> May 2008
- ||| AMG 337 / ImmunityBio, Amgen
Enrollment closed, Enrollment change: Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors (clinicaltrials.gov) - Jun 23, 2015
P2, N=60, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: May 2009 --> May 2008 Recruiting --> Active, not recruiting | N=140 --> 60
- | Enrollment closed, Metastases: Efficacy of Laparoscopic Subtotal Gastrectomy With D2 Lymph Node Dissection for Locally Advanced Gastric Cancer (clinicaltrials.gov) - Jun 23, 2015
P3, N=1050, Active, not recruiting, Sponsor: Ajou University School of Medicine
Recruiting --> Active, not recruiting | N=140 --> 60 Recruiting --> Active, not recruiting
- leucovorin calcium / Generic mfg., cisplatin / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Surgery: Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer (clinicaltrials.gov) - Jun 23, 2015
P2, N=39, Completed, Sponsor: ECOG-ACRIN Cancer Research Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed